|
|
Below you will find a full overview of Crucell’s R&D partners and licensees
Last update: December 18, 2008
|
|
 |
 |
  |
Preclinical |
 |
 |
Phase I |
 |
 |
Phase II |
 |
 |
Phase III |

|

|

|
|

|
|

|
|

|
|

|
| Gedeon Richter |
|
Nov. 2008 |
|
PER.C6® |
|
Undisclosed biopharmaceuticals |
|
- |
| Transgene |
|
Dec. 2007 |
|
PER.C6® |
|
Undisclosed vaccine |
|
 |
|
Merck & Co. Inc. |
|
Sep. 2007 |
|
PER.C6® + AdVac® |
|
2 infectious disease areas |
|

|
| Wyeth |
|
Jul 2007 |
|
PER.C6® + AdVac® |
|
Undisclosed vaccine |
|
- |
| Pfizer Animal Health |
|
Mar. 2007 |
|
PER.C6® |
|
Non-disclosed veterinary vaccine |
|

|
| ADImmune Corporation |
|
Oct. 2006 |
|
PER.C6® |
|
Japanese encephalitis virus |
|

|
|
Bestewil Holding BV |
|
Jan. 2006 |
|
Co-micelles |
|
Influenza |
|
- |
|
Tibotec Pharmaceuticals Ltd |
|
Nov. 2005 |
|
PER.C6® |
|
Undisclosed vaccine |
|

|
|
Singvax |
|
Mar. 2005 |
|
PER.C6® |
|
Japanese Encephalitis |
|

|
|
Chiron Corp. (Novartis) |
|
Dec. 2004 |
|
PER.C6® |
|
Alphavirus vectors |
|

|
|
Vaxin, Inc. |
|
Sep. 2004 |
|
PER.C6® |
|
Alzheimers disease |
|

|
|
International AIDS Vaccine Initiative (IAVI) |
|
Sep. 2004 |
|
AdVac® |
|
HIV |
|

|
|
National Institutes of Health (NIH) |
|
Mar. 2004 |
|
PER.C6® + AdVac® |
|
Malaria |
|

|
|
Aeras Global TB Vaccine Foundation |
|
Mar. 2004 |
|
PER.C6® + AdVac® |
|
Tuberculosis |
|

|
|
Sanofi Pasteur |
|
Dec. 2003 |
|
PER.C6® |
|
Influenza |
|

|
|
Kimron Veterinary Institute |
|
July 2003 |
|
PER.C6® |
|
West Nile Virus Veterinary vaccine (avian) |
|
Market
authorization in Israel |
|
Walter Reed Army Institute of Research & GSK Biologicals |
|
Mar. 2003 |
|
PER.C6® + AdVac® |
|
Malaria |
|

|
|
Harvard School of Medicine |
|
Oct. 2002 |
|
PER.C6® + AdVac® |
|
SIV |
|

|
|
NIH |
|
Mar. 2002 |
|
PER.C6® + AdVac® |
|
Ebola, Lassa and Marburg |
|

|
|
Merck & Co. Inc. |
|
Oct. 2000 |
|
PER.C6® |
|
Hepatitis C |
|

|
|
|
|

|

|
|

|
|

|
|

|
|

|
| CSL Ltd. |
|
Dec. 2008 |
|
PER.C6® |
|
Undisclosed protein |
|
- |
| GlaxoSmithKline |
|
Dec. 2008 |
|
PER.C6® |
|
Recombinant
protein |
|
- |
| Talecris Biotherapeutics |
|
Dec. 2008 |
|
PER.C6® |
|
Undisclosed protein |
|
- |
| Arana Therapeutics, Ltd |
|
Oct. 2008 |
|
PER.C6® |
|
Portfolio antibodies |
|
- |
| Abraxis Bioscience, Inc. |
|
Oct. 2008 |
|
PER.C6® |
|
Protein production |
|
- |
| Bioceros |
|
May 2008 |
|
STAR® |
|
Portfolio antibodies |
|
- |
| Toyobo Gene Analysis Co. LTD. |
|
Apr. 2008 |
|
STAR® |
|
Portfolio antibodies |
|
- |
| Celltrion, Inc. |
|
Apr. 2008 |
|
STAR® |
|
Portfolio antibodies |
|
- |
| Medarex Inc |
|
Mar. 2008 |
|
STAR® |
|
Monoclonal antibodies |
|
- |
|
MorphoSys A.G. |
|
Mar. 2008 |
|
PER.C6® |
|
Portfolio antibodies |
|
- |
| ISU ABXIS |
|
Jan. 2008 |
|
STAR® |
|
Portfolio antibodies |
|
Evaluation |
| Medarex Inc. |
|
Dec. 2007 |
|
PER.C6® |
|
Portfolio antibodies |
|
 |
|
ProFibrix |
|
Dec. 2007 |
|
STAR® |
|
Portfolio antibodies |
|
 |
| Daiichi Sankyo Ltd. |
|
Nov. 2007 |
|
PER.C6® |
|
Portfolio antibodies |
|
 |
| Recepta Biopharma S.A. |
|
Nov. 2007 |
|
PER.C6® |
|
Portfolio antibodies |
|
− |
|
MedImmune |
|
Oct. 2007 |
|
PER.C6® +
MAbstract® |
|
Anti-bacterial antibodies |
|
 |
| Invitrogen Corporation |
|
Sep. 2007 |
|
STAR® |
|
Monoclonal antibodies |
|
 |
|
LFB Biotechnologies |
|
July 2007 |
|
PER.C6® |
|
Undisclosed antibodies |
|
- |
| Masterclone |
|
July 2007 |
|
PER.C6® |
|
Undisclosed antibodies |
|
- |
| Sartorius Biotech GmbH |
|
June 2007 |
|
PER.C6® |
|
Portfolio antibodies |
|
|
| Development Center for Biotechnology (DCB) |
|
Mar. 2007 |
|
PER.C6® |
|
Undisclosed proteins |
|
|
| AbGenomics Corporation |
|
Jan. 2007 |
|
PER.C6® |
|
Monoclonal antibodies |
|
 |
| Biotecnol S.A. |
|
Dec. 2006 |
|
PER.C6® |
|
Portfolio antibodies |
|
 |
| Novartis |
|
Sep. 2006 |
|
STAR® |
|
Proteins, portfolio antibodies |
|
|
| UCB S.A. |
|
Sep. 2006 |
|
STAR® |
|
Monoclonal antibodies |
|
|
| MorphoSys A.G. |
|
Aug. 2006 |
|
PER.C6® |
|
Portfolio antibodies |
|
− |
|
Millennium Pharmaceuticals |
|
April 2006 |
|
STAR® |
|
Portfolio antibodies |
|

|
|
UMN Pharma |
|
Mar. 2006 |
|
PER.C6® |
|
Undisclosed protein |
|

|
|
XOMA Ltd |
|
Jan. 2006 |
|
STAR® |
|
Proteins, portfolio antibodies |
|
|
|
Ferring International Research Center S.A. |
|
Dec. 2005 |
|
PER.C6® |
|
Women’s healthcare |
|

|
|
Genzyme Corp. |
|
Dec. 2005 |
|
STAR® |
|
Portfolio proteins |
|

|
|
Zystor Therapeutics |
|
Dec. 2005 |
|
PER.C6® |
|
Undisclosed protein |
|

|
|
IQ Corp. |
|
Oct. 2005 |
|
PER.C6® |
|
Anti-anthrax antibody |
|

|
|
Medarex, Inc. |
|
Jun. 2005 |
|
STAR® |
|
− |
|
Evaluation |
|
Ferring International Research Center SA |
|
May 2005 |
|
PER.C6® |
|
Women’s healthcare |
|

|
|
Symphogen |
|
Apr. 2005 |
|
PER.C6® |
|
Portfolio antibodies |
|

|
|
Mitsubishi Pharma Corp. |
|
Mar. 2005 |
|
PER.C6® |
|
Undisclosed proteins |
|

|
|
Micromet A.G. |
|
Nov. 2004 |
|
PER.C6® |
|
Portfolio antibodies |
|

|
|
MorphoSys A.G. |
|
Sep. 2004 |
|
PER.C6® |
|
Portfolio antibodies |
|

|
|
Synergenics/ Synco Biopartners Investments B.V. |
|
Aug. 2004 |
|
PER.C6® |
|
Portfolio antibodies |
|

|
|
Chiron Corp. |
|
Jun. 2004 |
|
PER.C6® |
|
Portfolio antibodies |
|

|
|
Merus B.V. |
|
Jun. 2004 |
|
PER.C6® |
|
Portfolio oligoclonics |
|

|
|
Merck & Co., Inc. |
|
May 2003 |
|
PER.C6® |
|
Portfolio antibodies |
|

|
|
Genentech |
|
Feb. 2004 |
|
STAR® |
|
— |
|
Evaluation |
|
Applied Molecular Evolution, Inc. (Lilly) |
|
Oct. 2002 |
|
PER.C6® |
|
Portfolio antibodies |
|

|
|
|
|

|

|
|

|
|

|
|

|
|

|
|
Merial Ltd |
|
Dec. 2005 |
|
PER.C6® |
|
Veterinary |
|

|
|
Vascular Biogenics Ltd |
|
Mar. 2005 |
|
PER.C6® |
|
Portfolio |
|

|
|
NeoTropix |
|
Mar. 2004 |
|
PER.C6® |
|
Oncology |
|

|
|
TapImmune |
|
Aug. 2003 |
|
PER.C6® |
|
Portfolio |
|

|
|
Transgene SA |
|
April 2001 |
|
PER.C6® |
|
Portfolio |
|

|
|
Ark Therapeutics |
|
Nov. 2000 |
|
PER.C6® |
|
Portfolio |
|

|
|
Merck & Co., Inc. |
|
Nov. 1998 |
|
PER.C6® |
|
Portfolio |
|

|
|
|
|

|

|
|

|
|

|
|

|
|
Lonza |
|
Nov. 2008 |
|
PERMEXCIS™ |
|
Medium development |
|
Biochrom |
|
Nov. 2008 |
|
PERMEXCIS™ |
|
Medium development |
|
Invitrogen Corp. |
|
July 2006 |
|
PER.C6® |
|
Clone generation services |
|
Cambrex |
|
Aug. 2004 |
|
PER.C6® |
|
Medium development |
|
SAFC Biosciences Inc. |
|
May 2004 |
|
PER.C6® |
|
Medium development |
|
Sigma-Aldrich Corp. |
|
Dec. 2003 |
|
PER.C6® |
|
Medium development |
|
Hyclone, Inc. |
|
Dec. 2003 |
|
PER.C6® |
|
Medium development |
|
Gene Medicine Japan, Inc. |
|
Oct. 2003 |
|
PER.C6® |
|
Recombinant vaccines & gene therapy products (Asia) |
|
Invitrogen Corp. |
|
June 2003 |
|
PER.C6® |
|
Medium development |
|
DSM Biologics |
|
Dec. 2002 |
|
PER.C6® |
|
Therapeutic proteins (including antibodies) |
|
Molecular Medicine BioServices, Inc. |
|
Dec. 2001 |
|
PER.C6® |
|
Recombinant vaccines & gene therapy products (USA) |
|
|
|

|

|
|

|
|

|
|

|
|
Galapagos Genomics N.V. |
|
June 1999 |
|
PER.C6® |
|
Genomics |
|
|
|